PharmD, MPA, BCIDP Grant T Stimes, PharmD, BCIDP Brittany Rodriguez, PharmD Amanda Gillispie, MSN, MHA, RN, CPHON Tanya J Hilliard, MD, MSc Flor M Munoz, MD Lisa Forbes Satter
50 vs WA1). Evaluation of CH.1.1 and XBF by introducing variant-defining mutations into the replicon showed no change in in vitro susceptibility (< 1.8-fold change). Phenotyping of clinical isolates of BF.7, BQ.1, XBB.1.5, and CH.1.1 indicated no loss of RDV or ODV in vitro antiviral activity (< 1.3-fold change).
{ 'indexed': { 'date-parts': [[2023, 11, 27]],
'date-time': '2023-11-27T05:18:16Z',
'timestamp': 1701062296969},
'reference-count': 0,
'publisher': 'Oxford University Press (OUP)',
'issue': 'Supplement_2',
'license': [ { 'start': { 'date-parts': [[2023, 11, 27]],
'date-time': '2023-11-27T00:00:00Z',
'timestamp': 1701043200000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2023, 11, 27]]},
'abstract': '<jats:title>Abstract</jats:title>\n'
' <jats:sec>\n'
' <jats:title>Background</jats:title>\n'
' <jats:p>Texas Children’s Hospital (TCH) implemented an outpatient clinic '
'for eligible patients to receive infusions when COVID monoclonal antibodies (mAbs) were '
'approved for use in non-hospitalized, high-risk patients with mild to moderate COVID-19. '
'There are limited data evaluating the use of outpatient COVID mAbs in pediatric patients. We '
'describe the clinical characteristics and outcomes of the patients treated with COVID mAbs at '
'TCH.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Methods</jats:title>\n'
' <jats:p>Patients that were referred to receive COVID mAbs from 12/1/2020 to '
'5/5/2022 were included. Information collected included demographics, comorbidities, refusal '
'reason, adverse events, emergency center (EC) visits or admission within 14 days after final '
'dose, and EC visit or admission within 14 days of referral if patients did not receive COVID '
'mAbs. Chi-square was used to determine differences between the groups.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Results</jats:title>\n'
' <jats:p>There were 262 patients referred during the study period. The '
'median age of all referred patients was 15.8 years (IQR 14-17.4 years). Majority of referrals '
'were for treatment of COVID-19 infection rather than post-exposure prophylaxis (92.8% vs '
'7.2%). Of the 262 referrals, 134 patients received COVID mAbs (51.2%) while 128 patients were '
'not treated. Majority of the patients received casirivimab-imdevimab (73.9%). The '
'comorbidities of all patients are shown in Figure 1. The most common reasons for patients to '
'not receive COVID mAbs were no drug available or not listed, and the full list of reasons are '
'listed in Figure 2. The median time from reported symptom onset to infusion was 4 days (IQR '
'2-6 days). Of the 134 infused patients, 8 patients (6%) visited the EC within 14 days from '
'infusion, and 6 (4.5%) were admitted while 4 patients (3.1%) that did not receive an antibody '
'visited the EC resulting in 3 admissions (2.3%) (EC visits p=0.27; admissions p=0.34). There '
'were 11 patients (8.2%) that experienced adverse events from their infusion, which led to 5 '
'of the 8 EC visits. Comorbidities were similar across the infused and non-infused groups '
'(p=0.16).</jats:p>\n'
' <jats:p />\n'
' <jats:p>Number of high-risk conditions represented by all referred, '
'high-risk patients</jats:p>\n'
' <jats:p />\n'
' <jats:p>Number of patients for each reason for not receiving a COVID-19 '
'antibody infusion</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Conclusion</jats:title>\n'
' <jats:p>COVID mAb treatments were well tolerated among pediatric patients. '
'Majority of patients in both groups did not require EC visit or hospitalization. More data '
'are needed to determine the clinical efficacy of mAbs patients.</jats:p>\n'
' </jats:sec>\n'
' <jats:sec>\n'
' <jats:title>Disclosures</jats:title>\n'
' <jats:p>Flor M. Munoz, MD, MSc, CDC respiratory virus surveillance: '
'Grant/Research Support|Gilead: Grant/Research Support|Moderna, sanofi, aztra zeneca, Merck, '
'GSK: Advisor/Consultant|NIH: DSMB|NIH COVID-19 vaccines in pregnancy: Grant/Research '
'Support|Pfizer Pediatric COVID-19 vaccines: Grant/Research Support|Pfizer, Dynavax, Monderna, '
'Meissa, NIH: DSMB Lisa Forbes Satter, MD, ADMA: Advisor/Consultant|CsL Behring: '
'Advisor/Consultant|Grifols: Advisor/Consultant|incyte: Advisor/Consultant|Pharming: '
'Advisor/Consultant|Takeda: Advisor/Consultant</jats:p>\n'
' </jats:sec>',
'DOI': '10.1093/ofid/ofad500.615',
'type': 'journal-article',
'created': { 'date-parts': [[2023, 11, 27]],
'date-time': '2023-11-27T02:13:24Z',
'timestamp': 1701051204000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': '546. COVID-19 Monoclonal Antibody Use at a Stand Alone Children’s Hospital',
'prefix': '10.1093',
'volume': '10',
'author': [ { 'given': 'Grant T',
'family': 'Stimes',
'sequence': 'first',
'affiliation': [{'name': "Texas Children's Hospital , Houston, Texas"}]},
{ 'given': 'Brittany',
'family': 'Rodriguez',
'sequence': 'additional',
'affiliation': [{'name': "Texas Children's Hospital , Houston, Texas"}]},
{ 'given': 'Amanda',
'family': 'Gillispie',
'sequence': 'additional',
'affiliation': [{'name': "Texas Children's Hospital , Houston, Texas"}]},
{ 'given': 'Tanya J',
'family': 'Hilliard',
'sequence': 'additional',
'affiliation': [{'name': "Texas Children's Hospital , Houston, Texas"}]},
{ 'given': 'Flor M',
'family': 'Munoz',
'sequence': 'additional',
'affiliation': [{'name': 'Baylor College of Medicine , Houston, TX'}]},
{ 'given': 'Lisa Forbes',
'family': 'Satter',
'sequence': 'additional',
'affiliation': [{'name': 'Baylor College of Medicine , Houston, TX'}]}],
'member': '286',
'published-online': {'date-parts': [[2023, 11, 27]]},
'container-title': 'Open Forum Infectious Diseases',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.615/53772285/ofad500.615.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'syndication'},
{ 'URL': 'https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.615/53772285/ofad500.615.pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 11, 27]],
'date-time': '2023-11-27T02:13:25Z',
'timestamp': 1701051205000},
'score': 1,
'resource': { 'primary': { 'URL': 'https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofad500.615/7448106'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 11, 27]]},
'references-count': 0,
'journal-issue': {'issue': 'Supplement_2', 'published-print': {'date-parts': [[2023, 11, 27]]}},
'URL': 'http://dx.doi.org/10.1093/ofid/ofad500.615',
'relation': {},
'ISSN': ['2328-8957'],
'subject': ['Infectious Diseases', 'Oncology'],
'published-other': {'date-parts': [[2023, 12]]},
'published': {'date-parts': [[2023, 11, 27]]}}